Lung cancer in HIV-infected patients in the combination antiretroviral treatment era

José Moltó, Teresa Moran, Guillem Sirera, Bonaventura Clotet

Research output: Contribution to journalReview articleResearchpeer-review

9 Citations (Scopus)

Abstract

© Translational lung cancer research. The advent of combination antiretroviral treatment (cART) has been followed by a decrease in HIV-associated morbidity and mortality, but also by an apparent increase in the incidence of non-AIDSdefining cancers (NADCs). The risk of lung cancer is substantially higher in HIV-infected patients than in the general population, in part due to aging and tobacco use, and it is the most frequent NADC. The management of lung cancer in HIV-infected patients has some peculiarities that need to be taken into account. This review focuses on the epidemiology, risk factors, and clinical management of lung cancer in HIV-infected patients. In addition, screening tools and future perspectives are also discussed.
Original languageEnglish
Pages (from-to)678-688
JournalTranslational Lung Cancer Research
Volume4
Issue number6
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • Antiretroviral treatment
  • HIV infection
  • Lung cancer
  • Non-AIDS-defining cancers (NADCs)

Fingerprint Dive into the research topics of 'Lung cancer in HIV-infected patients in the combination antiretroviral treatment era'. Together they form a unique fingerprint.

Cite this